论文部分内容阅读
将113例口服降糖药治疗效果欠佳的T2DM患者随机分为57例观察组和56例对照组,观察组早餐前口服磷酸西格列汀并联合皮下注射地特胰岛素进行治疗,对照组早餐前口服磷酸西格列汀并联合皮下注射诺和灵30R进行治疗。结果:治疗后2组FPG、2h PG、HbA_(1C)均较治疗前显著降低(P<0.05),组间比较两组治疗后FPG、2h PG、HbA_(1C)无显著性差异(P>0.05)。观察组胰岛素用量显著少于对照组(P<0.05),低血糖发生率较对照组显著降低(P<0.05)。结论:磷酸西格列汀与地特胰岛素联合应用治疗T2DM效果良好。
The 113 patients with poor response to oral hypoglycemic treatment of T2DM were randomly divided into observation group 57 and 56 cases of control group, observation group before breakfast oral sitagliptin phosphate combined with subcutaneous injection of insulin detemir treatment, the control group breakfast Former oral administration of sitagliptin phosphate and subcutaneous injection of Novolin 30R for treatment. Results: The levels of FPG, 2h PG and HbA 1c in the two groups were significantly lower than those before treatment (P <0.05). There was no significant difference in FPG, 2h PG and HbA 1c between the two groups after treatment (P> 0.05). The dosage of insulin in the observation group was significantly less than that of the control group (P <0.05), and the incidence of hypoglycemia was significantly lower than that of the control group (P <0.05). Conclusion: The combination of sitagliptin phosphate and insulin detemir is effective in treating T2DM.